ARCHIMED Acquires Majority Stake in Arkstone

ARCHIMED has acquired a majority stake in Arkstone Medical Solutions, a biotechnology company known for its AI-driven clinical decision support systems. This acquisition, announced in a press release, aims to enhance Arkstone's global reach and accelerate its research and development capabilities.

Arkstone's flagship product, the OneChoice Report, utilizes machine learning and AI to provide precise infectious disease treatment recommendations by analyzing laboratory results and patient data. This tool is already in use across various laboratories in the United States and internationally, transforming how healthcare providers diagnose and treat infectious diseases.

With ARCHIMED's investment and expertise, Arkstone plans to expand its market presence and further develop its products to combat antimicrobial resistance, a significant public health challenge. The acquisition will allow Arkstone to continue operating with its existing team while focusing on rapid growth and innovation.